- I was drawn to Halozyme due to its business model that is devoid of in-house drug development. Halozyme reformulates many blockbuster drugs that provided them with significant milestones and royalty.
- What is more, the impressive number of partners diversifies their revenue sources and clinical success.
- The company’s growth trends have remained intact throughout the pandemic and are projected to endure several more years.
- Now, I am moving HALO into my “Top Ideas” list considering the company's recent earnings and commercial success.
For further details see:
Halozyme: Steady Revenue Growth At A Reasonable Valuation